Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Rating of “Hold” from Brokerages

Atossa Genetics Inc. (NASDAQ:ATOS) has been assigned an average rating of “Hold” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $68.3333.

A number of brokerages have recently commented on ATOS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. HC Wainwright upped their price target on Atossa Genetics to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 26th.

Atossa Genetics Stock Down 5.2%

NASDAQ:ATOS opened at $4.88 on Wednesday. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35. The firm has a market cap of $42.02 million, a price-to-earnings ratio of -1.36 and a beta of 1.34. The company’s 50 day moving average is $5.08 and its 200-day moving average is $9.53.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ATOS. Bank of America Corp DE lifted its holdings in shares of Atossa Genetics by 51.3% during the fourth quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock worth $105,000 after buying an additional 37,809 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after buying an additional 325,340 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Atossa Genetics during the second quarter worth approximately $381,000. Ameriprise Financial Inc. acquired a new position in shares of Atossa Genetics during the second quarter worth approximately $2,468,000. Finally, Hudson Bay Capital Management LP acquired a new position in shares of Atossa Genetics in the second quarter valued at $26,000. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.